*The following content is generated by AI and is for reference only.
Overview
BIBW2992, known as Brigatinib, is a second-generation tyrosine kinase inhibitor developed for targeted oncology therapy. It functions via an optimized covalent binding mechanism to inhibit ALK and EGFR pathways. The compound features the molecular formula C24H28N6O3 and carries CAS registry number 1507275-08-6.
Application
- Non-Small Cell Lung Cancer (NSCLC): First-line treatment for ALK-positive metastatic NSCLC.
- Resistance Management: Effective against T790M mutation-mediated resistance in EGFR-mutated cases.
- Clinical Trials: Investigational use in solid tumors exhibiting specific kinase alterations.
Precautions
Strictly prescribed under medical supervision due to risks of interstitial lung disease and hepatotoxicity. Storage requires maintaining temperatures between 20°C and 25°C in moisture-proof containers with controlled humidity levels.